MARKET

HRTX

HRTX

Heron Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.09
+0.01
+0.06%
Pre Market: 18.03 -0.06 -0.33% 09:26 03/02 EST
OPEN
18.41
PREV CLOSE
18.08
HIGH
18.62
LOW
17.88
VOLUME
25
TURNOVER
--
52 WEEK HIGH
22.40
52 WEEK LOW
9.60
MARKET CAP
1.65B
P/E (TTM)
-7.2262
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Global Meloxicam Market Research Report 2020-2026
Feb 27, 2021 (Heraldkeepers) -- The global Meloxicam market is valued at US$ xx million in 2019 is expected to reach US$ xx million by the end of 2026,...
Heraldkeepers · 3d ago
Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
Zacks.com · 5d ago
8-K: HERON THERAPEUTICS, INC. /DE/
(EDGAR Online via COMTEX) -- false 0000818033 0000818033 2021-02-24 2021-02-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 5d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Heron Therapeutics (HRTX) and LivaNova (LIVN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Heron Therapeutics (HRTX) and LivaNova (LIVN). Heron Therapeutics (HRTX)
SmarterAnalyst · 5d ago
Northland Securities Remains a Buy on Heron Therapeutics (HRTX)
Northland Securities analyst Carl Byrnes reiterated a Buy rating on Heron Therapeutics (HRTX) today and set a price target of $35.00. The company's shares
SmarterAnalyst · 5d ago
Stifel Nicolaus Keeps Their Buy Rating on Heron Therapeutics (HRTX)
Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Heron Therapeutics (HRTX) today and set a price target of $28.00. The company's shares
SmarterAnalyst · 5d ago
BRIEF-Heron Therapeutics Q4 Loss Per Share $0.68
reuters.com · 5d ago
Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
Zacks.com · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HRTX. Analyze the recent business situations of Heron Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HRTX stock price target is 33.40 with a high estimate of 70.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 317
Institutional Holdings: 110.32M
% Owned: 120.71%
Shares Outstanding: 91.40M
TypeInstitutionsShares
Increased
52
7.75M
New
39
-5.70M
Decreased
63
2.44M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.13%
Pharmaceuticals & Medical Research
+1.38%
Key Executives
Chairman/Chief Executive Officer/Director
Barry Quart
President
John Poyhonen
Chief Operating Officer/Executive Vice President
David Szekeres
Executive Vice President/Director
Kimberly Manhard
Senior Vice President/Chief Scientific Officer
Thomas Ottoboni
Senior Vice President
Anita Gupta
Senior Vice President
Michael Mathews
Chief Accounting Officer/Vice President
Lisa Peraza
Vice President/Director of Human Resources
Sean Ristine
Vice President
John Arthur
Other
Christopher Storgard
Lead Director/Independent Director
Craig Johnson
Director
Steve Davis
Independent Director
Stephen Davis
Independent Director
Christian Waage
  • Dividends
  • Splits
  • Insider Activity
No Data
About HRTX
Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Webull offers kinds of Heron Therapeutics Inc stock information, including NASDAQ:HRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HRTX stock methods without spending real money on the virtual paper trading platform.